PDF) The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients with Severe Hemophilia A: A Retrospective Analysis from the ReCARE Study
Haemophilia Timeline - Haemnet
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial | ResearchGate
ヌーイック静注用 250 ヌーイック静注用 500 ヌーイック静注用 1000 ヌーイック静注用 2000 ヌーイ
PDF) Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial | ResearchGate
PDF) Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: Insights from two clinical trials on turoctocog alfa
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. - Abstract - Europe PMC
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A | SpringerLink
PDF) von Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A
ABSTRACT BOOK
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in
Personalizing the Management of Hemophilia: A CME Supplement
PDF) Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial
Long‐term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial - Lentz - 2018 - Haemophilia - Wiley Online Library
PDF) Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: Insights from two clinical trials on turoctocog alfa
PDF) A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A. - Abstract - Europe PMC
Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial - Yaish -
